STOCKHOLM--(BUSINESS WIRE)--Medivir (STO:MVIRB): •Consolidated net sales were SEK 36.2 (24.5) m. •The consolidated loss for the period was SEK -50.3 (-62.9) m. •Earnings per share for the period were SEK -2.14 (-3.02). •Cash flow from operating activities was SEK 4.6 (-72.9) m. •Cash and cash equivalents and investments in securities etc. at the end of the period were SEK 462.7 (210.9) m.
